Business Context and Reporting Period
This Form 8-K, dated November 11, 2025, reports on Salarius Pharmaceuticals, Inc. (SLRX). The filing details a public equity offering and the completion of a merger with Decoy Therapeutics Inc. (Decoy). The offering closed on November 12, 2025, and the merger was consummated on the same date, making Decoy a wholly-owned subsidiary of Salarius.
Key Financial Metrics and Capital Structure
- Net Proceeds: Approximately $6.3 million from the public offering, after deducting underwriting discounts and estimated expenses.
- Offering Price: $1.50 per share of Common Stock (plus warrants); $1.4999 per pre-funded warrant (plus warrants).
- Securities Issued:
- 2,514,335 shares of Common Stock.
- 2,152,331 pre-funded warrants.
- Series A and Series B warrants to purchase up to 4,666,666 shares each.
- Exercise of over-allotment option for an additional 665,729 shares and corresponding warrants.
- Post-Closing Capitalization: 4,231,846 shares of Common Stock outstanding immediately after closing, plus pre-funded warrants for 2,152,331 shares.
- Debt Repayment: Proceeds are designated to pay off certain outstanding promissory notes of Decoy Therapeutics Inc.
Material Changes and Merger Details
Salarius completed a merger with Decoy Therapeutics Inc. pursuant to an Agreement and Plan of Merger originally dated January 10, 2025. Key terms include:
- Consideration to Decoy Stakeholders: Issuance of 877,709 shares of Series A Non-Voting Convertible Preferred Stock and 796,306 shares of Series B Non-Voting Convertible Preferred Stock.
- Conversion Ratio Adjustment: Due to the offering price being below the $3.75 floor price in the Certificate of Designation, the conversion ratio for both Series A and Series B Preferred Stock was reset to 2,800:1.
- Total Underlying Shares: The issued and reserved preferred stock represents 4,814,106 underlying common shares.
- Redemption Provisions: Series B Preferred Stock is subject to mandatory redemption using 50% of net proceeds from future At-the-Market (ATM) sales or equity line drawdowns.
Management Changes, Governance, and Risks
Leadership Appointments
Effective November 12, 2025, the following changes occurred:
- CEO: Frederick E. Pierce (former Decoy CEO) appointed as CEO. Mark Rosenblum steps down as active CEO but remains Executive Vice President and CFO.
- CSO: Dr. Barbara Hibner (former Decoy CSO) appointed as Chief Scientific Officer.
- CBO: Peter Marschel (former Decoy CBO) appointed as Chief Business Officer.
- Board: Mr. Pierce appointed as a Class II Director; Dr. Bruce J. McCreedy resigned.
Lock-Up and Restrictions
- Company Lock-Up: 60 days for equity issuances; 6 months for variable rate transactions.
- Insider Lock-Up: Officers and directors are restricted from selling securities for 180 days.
- Warrant Restrictions: Beneficial ownership limitations cap conversions at 4.99% (electable to 9.99%) of outstanding common stock.
Risks and Contingencies
The filing contains forward-looking statements regarding the use of proceeds and future performance. Risks include the dilutive impact of the preferred stock conversion, the requirement for stockholder and Nasdaq approval to convert preferred stock, and the company's reliance on future financing to fund operations.
Investor Verification Checklist
- Verify the conversion ratio of Series A and Series B Preferred Stock (currently 2,800:1) and the total number of common shares issuable upon conversion (4,814,106).
- Confirm the redemption obligations for Series B Preferred Stock, specifically the requirement to use 50% of future ATM proceeds for redemption.
- Review the lock-up agreements for the 180-day insider restriction and the 60-day/6-month company restrictions on new issuances.
- Check the status of Nasdaq listing approval and stockholder approval required to convert the preferred stock into common stock.
- Examine the use of proceeds to ensure the repayment of Decoy's promissory notes is executed as planned.